Compare AXSM & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXSM | ITGR |
|---|---|---|
| Founded | 2012 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 2.4B |
| IPO Year | 2015 | 2000 |
| Metric | AXSM | ITGR |
|---|---|---|
| Price | $148.16 | $72.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 8 |
| Target Price | ★ $176.00 | $93.71 |
| AVG Volume (30 Days) | 526.6K | ★ 585.3K |
| Earning Date | 11-03-2025 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.42 |
| Revenue | $561,263,000.00 | ★ $1,831,074,000.00 |
| Revenue This Year | $66.20 | $9.58 |
| Revenue Next Year | $57.56 | N/A |
| P/E Ratio | ★ N/A | $29.99 |
| Revenue Growth | ★ 65.83 | 9.54 |
| 52 Week Low | $75.56 | $62.00 |
| 52 Week High | $152.94 | $146.36 |
| Indicator | AXSM | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 50.43 |
| Support Level | $144.00 | $69.12 |
| Resistance Level | $150.00 | $73.49 |
| Average True Range (ATR) | 4.15 | 1.61 |
| MACD | -0.73 | 1.06 |
| Stochastic Oscillator | 57.42 | 85.81 |
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.